Sophie Betteridge

An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation

Paul Ferguson, Robert K. Hills, Angela Grech et al. · Haematologica · 2016 · 94 citations · Full text

Medicine, Oncology, Chemotherapy +9

A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial

Jad Othman, Charlotte S. Wilhelm-Benartzi, Richard Dillon et al. · Blood Advances · 2023 · 54 citations · Full text

Medicine, Hematology, Oncology +17

Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With <i>NPM1</i> and <i>FLT3</i> Mutations

Nigel H. Russell, Charlotte S. Wilhelm-Benartzi, Jad Othman et al. · Journal of Clinical Oncology · 2024 · 41 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Nocebo effects and participant information leaflets: evaluating information provided on adverse effects in UK clinical trials

Nigel Kirby, Victoria Shepherd, Jeremey Howick et al. · Trials · 2020 · 39 citations · Full text

Pharmacy, Pharmacology, Clinical Pharmacology +12

Addition of the mammalian target of rapamycin inhibitor, everolimus, to consolidation therapy in acute myeloid leukemia: experience from the UK NCRI AML17 trial

Alan K. Burnett, Emma Das gupta, Steven Knapper et al. · Haematologica · 2018 · 19 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16